Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncologist. 2010;15(12):1262-9. doi: 10.1634/theoncologist.2010-0196. Epub 2010 Dec 8.

Inhibitors of mTOR.

Author information

1
Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. h.klumpen@amc.nl

Abstract

Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.

PMID:
21147869
PMCID:
PMC3227930
DOI:
10.1634/theoncologist.2010-0196
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center